StockData

Cerenome vs Neuroone Medical Technologies

CNSY and NMTC side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CNSY and NMTC compare

Neuroone Medical Technologies is the larger company, worth 1.3 times as much as Cerenome ($6.4M against $4.8M).

Neuroone Medical Technologies grew revenue faster over the last twelve months (42.8% versus −21.0% for Cerenome).

Neuroone Medical Technologies keeps more of each dollar of sales as profit, with a net margin of −78.6% compared with −621% at Cerenome.

Neuroone Medical Technologies scores higher on the StockData Score (11 against 8 for Cerenome), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCNSYNMTC
Size and price
Market cap$4.8M$6.4M
Share price$0.630$0.707
Change, 1 year−95.1%−82.9%
Change, 5 years−98.3%−94.8%
Beta (5Y)4.920.40
Employees2818
StockData Score
Total score811 (better)
Valuation score33
Growth score12 (better)
Performance score01 (better)
Health score45 (better)
Dividend score00
Valuation
P/S1.1×0.7× (better)
P/B0.9× (better)1.7×
FCF yield−492%−111% (better)
Fair value$2.14$3.52
Margin of safety70.5%80.0% (better)
Growth
Revenue growth (TTM)−21.0%42.8% (better)
Profitability
Gross margin–55.6%
Operating margin−628%−83.4% (better)
Net margin−621%−78.6% (better)
FCF margin−560%−75.6% (better)
Return on equity−614%−125% (better)
Return on invested capital–−672%
Financial health
Debt / equity0.000.00
Interest coverage−1200.0×–
Current ratio1.372.84 (better)
Altman Z-score−58.37−19.47 (better)
Piotroski F-score46 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions8.3%22.7%
Held by insiders4.2%85.4%
Insider net buying, 12 months$0$682K (better)
Short interest, % of float11.6%15.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.